Incidentally, Dasgupta attended the midnight event at
the Central Hall of Parliament for the GST launch on
July 1, where his contribution was publicly acknowledged
by Union Finance Minister Arun Jaitley.
Dasgupta, however, said the committee had emphasised a
concept of "floor rate and a band around that to uphold
the autonomy of the states in choosing the rates,"
particularly the general rate.
"It is noted that even in the Constitution Amendment
(2016) for GST, this provision of choosing of band with
floor rate was specifically mentioned in clause 279. But
the GST Council fell short of it," he said.
Asked why petroleum products were not brought into the
ambit of GST, Dasgupta said: "There were apprehensions
in the minds of the state governments that their revenue
would slide with the introduction of the new indirect
tax structure."
"In fact, around 30 per cent of the states' sales tax
revenue is obtained from petroleum products. That is why
state governments proposed to keep the inclusion of the
petroleum products group in abeyance, particularly
during the initial years of the GST regime."
Petroleum products will become part of the GST structure
later, said Dasgupta,who holds a doctorate from the
Massachusetts Institute of Technology.
Dasgupta felt GST should not lead to inflation.
"Before the introduction of GST, the weighted average of
tax burden of all the indirect taxes of both the Centre
and states at the previously existing rates was around
23 per cent while in the GST regime, it has come down to
around 18 per cent. This has happened because the input
tax credit net is wider now," he said.
Commenting on the GST rates on medicines, he said in the
context of introducing a state-level Value Added Tax
(VAT), the committee had, for medicines, recommended a
total exemption of tax for life-saving drugs and lower
rate of five per cent for the remaining drugs.
Commenting on the GST rates on medicines, he said in the
context of introducing a state-level Value Added Tax
(VAT), the committee had, for medicines, recommended a
total exemption of tax for life-saving drugs and lower
rate of five per cent for the remaining drugs.
"I cannot quite agree with the present recommendation of
the GST Council for inclusion of a much smaller number
of medicines in the exempted category and remaining
medicines in the 12 per cent and 18 per cent
categories," Dasgupta said.
Recalling the story of indirect tax structure reforms in
India, he said with the introduction of VAT, the issue
of tax-on-tax and related burden of cascading effect was
removed as a set-off was given from the tax burden not
only for input tax paid but also for tax paid on
previous purchases.
There was a "built-in check in the VAT structure on tax
compliance" in the Centre as well as in the states, he
said.
"As a result, it was found, if you take the five years
before the introduction of the state VAT, the average
annual rate of growth of the then sales tax was 11 per
cent and if you take the next five years after the
introduction of VAT, the average rate of growth of tax
revenue doubled to 22 per cent," Dasgupta said.
But there were some deficiencies in the VAT regime and
in terms of tax reforms, GST was logically the next
step, he added.
Source::: The Economic Times,
dated 28/07/2017.